View in EDS

Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.

Saved in:
Bibliographic Details
Title: Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.
Authors: Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Lee D; Yale School of Medicine, New Haven, USA., Foldi J; University of Pittsburgh School of Medicine, Pittsburgh, USA., Soulos PR; Yale School of Medicine, New Haven, USA., Gross CP; Yale School of Medicine, New Haven, USA., Grinda T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Winer EP; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Krop IE; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Lustberg M; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: Sarahl_Sammons@dfci.harvard.edu.
Source: ESMO open [ESMO Open] 2025 Jul; Vol. 10 (7), pp. 105330. Date of Electronic Publication: 2025 Jun 18.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40532362
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tarantino+P%22">Tarantino P</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Lee+D%22">Lee D</searchLink>; Yale School of Medicine, New Haven, USA.<br /><searchLink fieldCode="AU" term="%22Foldi+J%22">Foldi J</searchLink>; University of Pittsburgh School of Medicine, Pittsburgh, USA.<br /><searchLink fieldCode="AU" term="%22Soulos+PR%22">Soulos PR</searchLink>; Yale School of Medicine, New Haven, USA.<br /><searchLink fieldCode="AU" term="%22Gross+CP%22">Gross CP</searchLink>; Yale School of Medicine, New Haven, USA.<br /><searchLink fieldCode="AU" term="%22Grinda+T%22">Grinda T</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Winer+EP%22">Winer EP</searchLink>; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA.<br /><searchLink fieldCode="AU" term="%22Lin+NU%22">Lin NU</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Krop+IE%22">Krop IE</searchLink>; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Lustberg+M%22">Lustberg M</searchLink>; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA.<br /><searchLink fieldCode="AU" term="%22Sammons+S%22">Sammons S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: Sarahl_Sammons@dfci.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101690685%22">ESMO open</searchLink> [ESMO Open] 2025 Jul; Vol. 10 (7), pp. 105330. <i>Date of Electronic Publication: </i>2025 Jun 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101690685 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-7029 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220597029%22">20597029 </searchLink><i>NLM ISO Abbreviation: </i>ESMO Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40532362
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.esmoop.2025.105330
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 105330
    Titles:
      – TitleFull: Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tarantino P
      – PersonEntity:
          Name:
            NameFull: Lee D
      – PersonEntity:
          Name:
            NameFull: Foldi J
      – PersonEntity:
          Name:
            NameFull: Soulos PR
      – PersonEntity:
          Name:
            NameFull: Gross CP
      – PersonEntity:
          Name:
            NameFull: Grinda T
      – PersonEntity:
          Name:
            NameFull: Winer EP
      – PersonEntity:
          Name:
            NameFull: Lin NU
      – PersonEntity:
          Name:
            NameFull: Krop IE
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
      – PersonEntity:
          Name:
            NameFull: Lustberg M
      – PersonEntity:
          Name:
            NameFull: Sammons S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2059-7029
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: ESMO open
              Type: main
ResultId 1